Key Takeaways from the PARADIGM Study
Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.
Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency
A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.
A Cross-Sectional Survey Reveals Physicians’ Treatment Patterns in First-Line and Maintenance Therapy for la/mUC
Drs Gupta and Makkar discuss results from the PARADIGM cross-sectional survey, which reveals physicians’ 1L and 1LM treatment patterns in la/mUC.
Perspectives on First-Line Treatment Decision-Making for la/mUC: Results of The Targeted Literature Search and Qualitative Interviews
Experts discuss results from the targeted literature search and qualitative interviews, which identify important factors that impact their treatment decisions for patients with locally advanced/metastatic urothelial carcinoma.
Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making
Shilpa Gupta, MD, describes the scope and methods of the PARADIGM study, which examines recent systemic anti-cancer treatment patterns in la/mUC.
Overview of Locally Advanced/Metastatic Urothelial Carcinoma
Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.
